Sonoma Pharmaceuticals - SNOA Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.01
▼ -0.09 (-2.90%)

This chart shows the closing price for SNOA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sonoma Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNOA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNOA

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Sonoma Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.01.

This chart shows the closing price for SNOA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Sonoma Pharmaceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/19/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/20/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2018Maxim GroupReiterated RatingHoldHigh
7/20/2018BenchmarkReiterated RatingSpeculative Buy$3.00Medium
3/5/2018Maxim GroupDowngradeBuy ➝ Hold$7.00Low
2/14/2018Maxim GroupReiterated RatingBuy ➝ Buy$11.00 ➝ $7.00Low
2/8/2018Maxim GroupSet TargetBuy$11.00 ➝ $7.00High
12/28/2017BenchmarkInitiated CoverageSpeculative Buy ➝ Speculative Buy$10.00High
11/17/2017Maxim GroupSet TargetBuy$11.00N/A
11/10/2017Maxim GroupBoost TargetBuy$10.00 ➝ $11.00N/A
(Data available from 8/18/2017 forward)

News Sentiment Rating

0.68 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/20/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/19/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/21/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/20/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/20/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/19/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/19/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/18/2022

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Sonoma Pharmaceuticals logo
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
Read More

Today's Range

Now: $3.01
Low: $2.95
High: $3.08

50 Day Range

MA: $3.09
Low: $2.83
High: $3.66

52 Week Range

Now: $3.01
Low: $2.55
High: $13.36

Volume

58,060 shs

Average Volume

125,657 shs

Market Capitalization

$9.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97

Frequently Asked Questions

What sell-side analysts currently cover shares of Sonoma Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Sonoma Pharmaceuticals in the last twelve months:
View the latest analyst ratings for SNOA.

What is the current price target for Sonoma Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Sonoma Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Sonoma Pharmaceuticals in the next year.
View the latest price targets for SNOA.

What is the current consensus analyst rating for Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SNOA.

What other companies compete with Sonoma Pharmaceuticals?

How do I contact Sonoma Pharmaceuticals' investor relations team?

Sonoma Pharmaceuticals' physical mailing address is 645 MOLLY LANE SUITE 150, WOODSTOCK GA, 30189. The company's listed phone number is (800) 759-9305 and its investor relations email address is [email protected] The official website for Sonoma Pharmaceuticals is www.sonomapharma.com. Learn More about contacing Sonoma Pharmaceuticals investor relations.